Golden State Equity Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Golden State Equity Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.8K	Buy	+200	New	+$21.3K	﹤0.01%	1086

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

Golden State Equity Partners's PPH Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in VanEck Pharmaceutical ETF (PPH) in Q1 2026: 200 shares worth $20.8K. The stake represents ﹤0.01% of the portfolio and ranks #1086 among its holdings.

147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

Golden State Equity Partners held 200 shares of VanEck Pharmaceutical ETF worth $20.8K as of Q1 2026.
VanEck Pharmaceutical ETF was a new Golden State Equity Partners position in Q1 2026.
VanEck Pharmaceutical ETF made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1086 holding.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.